Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 3NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 2Dermatologic 1CNS 1

Conditions

Thyroid Neoplasms 31Thyroid Cancer, Papillary 26Pheochromocytoma 23Adenocarcinoma, Follicular 23Adrenocortical Carcinoma 21Neuroendocrine Tumors 20Carcinoma, Medullary 17Somatostatinoma 14Insulinoma 14Thyroid Carcinoma, Anaplastic 13Pituitary Neoplasms 13Paraganglioma 13Carcinoma, Neuroendocrine 12Glucagonoma 11Carcinoma, Renal Cell 11Parathyroid Neoplasms 10Pancreatic Neoplasms 10Gastrinoma 10Carcinoma, Non-Small-Cell Lung 10Carcinoma, Hepatocellular 10Head and Neck Neoplasms 9Colonic Neoplasms 9Carcinoma, Islet Cell 9Breast Neoplasms 9Small Cell Lung Carcinoma 8Sarcoma 8Neoplasms 8Rectal Neoplasms 7Multiple Endocrine Neoplasia Type 1 7Adrenal Gland Neoplasms 7

Interventions

pazopanib 1cixutumumab 1Salts 1Octreotide 1Everolimus 1Acetates 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Zollinger-Ellison Syndrome × Endocrine × Clear all
NCT00454363 2020-04-03

Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer

National Cancer Institute (NCI)

Phase 2 Completed
52 enrolled 11 charts
Endocrine

Glucagonoma, Insulinoma, Somatostatinoma, Zollinger-Ellison Syndrome, Multiple Endocrine Neoplasia Type 1

NCT01204476 2016-07-15

Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma

National Cancer Institute (NCI)

Phase 1 Completed
27 enrolled
CNSDermatologicEndocrine

Glucagonoma, Insulinoma, Paraganglioma, Somatostatinoma, Zollinger-Ellison Syndrome, Carcinoma, Merkel Cell, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡